Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Sullivan, HC ;
Gerner-Smidt, C ;
Nooka, AK ;
Arthur, CM ;
Thompson, L ;
Mener, A ;
Patel, SR ;
Yee, M ;
Fasano, RM ;
Josephson, CD ;
Kaufman, RM ;
Roback, JD ;
Lonial, S ;
Stowell, SR

Center for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine. Department of Hematology and Medical Oncology, and. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; and. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Blood. 2017;(22):3033-3037

Full text from:

Elsevier Science
Silverchair Information Systems

Methodological quality

Publication Type : Clinical Trial ; Multicenter Study

Metadata

MeSH terms : ADP-ribosyl Cyclase 1 ; Membrane Glycoproteins

Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Other resources

Methodological quality

Metadata